Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

NCT04672772 · clinicaltrials.gov ↗

COMPLETED

Status

531

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Cetuximab
DRUG: Paclitaxel

Sponsor

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Collaborators

[object Object]